Table 2 Univariate analysis for OS of CML-BC.

From: Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

Variable

All, n = 99

TKI treated, n = 59

Univariate

Adjusted

Univariate

Adjusted

n

HR

95% CI

P

HR

95% CI

P

n

HR

95% CI

P

HR

95% CI

P

Clinical factors

  Age at BC (>60 y)

27

1.26

0.76–2.10

0.36

1.89

1.08–3.31

2.5 × 10−2*

19

1.34

0.68–2.63

0.40

1.35

0.68–2.67

0.39

  Sex (male)

59

0.98

0.62–1.55

0.92

1.01

0.63–1.62

0.97

37

0.85

0.44–1.63

0.62

0.87

0.45–1.68

0.68

  WBC (>50,000 × 103/uL)

50

0.77

0.49–1.23

0.27

0.73

0.46–1.17

0.19

27

0.50

0.26–0.96

3.6 × 10−2*

—

—

—

  Hb (<9.3 g/dL)

49

1.19

0.75–1.87

0.46

0.79

0.49–1.27

0.32

25

1.20

0.63–2.27

0.58

1.07

0.55–2.08

0.85

  Plt (<96,000 × 103/uL)

49

0.92

0.58–1.44

0.70

1.38

0.83–2.27

0.21

30

1.16

0.61–2.22

0.64

1.20

0.60–2.41

0.61

  Lineage of blasts (myeloid)

64

2.59

1.53–4.39

3.8 × 10−4***

—

—

—

33

2.08

1.06–4.07

3.3 × 10−2*

—

—

—

  Prior history of TKI before BC

36

0.93

0.58–1.51

0.78

1.05

0.64–1.73

0.84

26

1.41

0.74–2.70

0.29

0.70

0.32–1.56

0.39

  TKI-based therapy for BC

59

0.36

0.23–0.58

2.0 × 10−5***

—

—

—

59

—

—

—

—

—

—

Mutations

  ABL1

13

1.11

0.58–2.11

0.75

1.17

0.62–2.23

0.63

8

1.55

0.67–3.55

0.30

1.09

0.46–2.59

0.85

  ASXL1

23

2.09

1.26–3.47

4.4 × 10−3**

1.30

0.76–2.25

0.34

11

2.31

1.08–4.91

3.0 × 10−2*

2.61

1.07–6.37

3.4 × 10−2*

  BCOR

5

1.58

0.63–3.96

0.33

1.75

0.69–4.42

0.24

4

2.99

1.03–8.70

4.4 × 10−2*

2.57

0.84–7.85

9.7 × 10−2

  BCORL1

5

1.41

0.57–3.49

0.46

1.34

0.53–3.41

0.54

3

1.44

0.44–4.72

0.55

0.90

0.27–3.07

0.87

  CDKN2A/B

7

0.95

0.41–2.19

0.91

1.84

0.70–4.87

0.22

5

1.97

0.75–5.17

0.17

2.82

0.87–9.13

8.4 × 10−2

  IKZF1

12

0.61

0.27–1.41

0.25

1.03

0.42–2.53

0.95

10

1.09

0.42–2.81

0.86

1.87

0.65–5.35

0.24

  RUNX1

28

1.02

0.63–1.67

0.93

1.06

0.64–1.76

0.81

21

1.45

0.76–2.77

0.26

1.68

0.86–3.27

0.13

  TP53

8

1.62

0.74–3.53

0.23

1.46

0.66–3.22

0.35

3

0.90

0.22–3.75

0.88

0.80

0.19–3.36

0.76

CNAs

  +Ph

26

1.44

0.87–2.36

0.16

1.28

0.78–2.12

0.33

14

1.71

0.84–3.46

0.14

1.46

0.72–2.97

0.29

  Complex CNAs

28

1.65

1.02–2.67

4.3 × 10−2*

1.66

1.00–2.73

4.8 × 10−2*

16

2.99

1.55–5.78

1.1 × 10−3**

3.37

1.69–6.69

5.3 × 10−4***

  Hyperdiploidy

6

4.38

1.84–10.5

8.7 × 10−4***

2.28

0.93–5.57

7.0 × 10−2

1

10.99

1.28–94.1

2.9 × 10−2*

5.90

0.67–51.7

0.11

  +6

6

0.91

0.33–2.52

0.86

0.75

0.27–2.08

0.58

2

0.63

0.08–4.65

0.65

0.21

0.03–1.68

0.14

  −7/del(7p)

13

0.89

0.46–1.74

0.74

2.41

1.06–5.45

3.5 × 10−2*

9

0.84

0.35–2.01

0.69

1.63

0.56–4.72

0.37

  +8

18

1.29

0.72–2.32

0.39

0.91

0.50–1.65

0.76

8

1.08

0.42–2.80

0.88

0.46

0.16–1.32

0.15

  −9/del(9p)

9

0.87

0.40–1.89

0.72

1.30

0.52–3.25

0.57

5

1.97

0.75–5.17

0.17

2.82

0.87–9.13

8.4 × 10−2

  del(17p)

13

2.78

1.50–5.18

1.2 × 10−3**

1.78

0.94–3.38

7.6 × 10−2

5

4.54

1.63–12.6

3.8 × 10−3**

2.86

0.97–8.44

5.6 × 10−2

  amp(17q)

7

1.98

0.90–4.34

8.8 × 10−2

2.44

1.10–5.45

2.9 × 10−2*

5

2.59

1.00–6.73

5.0 × 10−2

2.62

0.98–6.99

5.5 × 10−2

  i(17q)

4

2.81

1.00–7.84

4.9 × 10−2*

2.79

0.98–7.91

5.4 × 10−2

3

5.50

1.58–19.2

7.5 × 10−3**

2.89

0.78–10.7

0.11

  +19

13

2.85

1.54–5.27

8.4 × 10−4***

1.66

0.87–3.18

0.12

4

4.48

1.49–13.5

7.5 × 10−3**

3.09

0.98–9.71

5.3 × 10−2

  +21

11

2.63

1.37–5.05

3.6 × 10−3**

1.69

0.87–3.31

0.12

5

3.93

1.49–10.4

5.7 × 10−3**

3.23

1.16–8.97

2.4 × 10−2*

  1. Univariate analysis for OS by Cox proportional hazard regression model. For all cases (n = 99), values adjusted for lineage of blasts and TKI-containing therapy for BC are also shown. For TKI treated cases (n = 59), values adjusted for WBC and lineage of blasts are also shown. Information for prior history of TKI is missing in two patients treated by TKI for BC.
  2. 95% CI 95% confidence interval, HR hazard ratio.
  3. *P < 0.05; **P < 0.01; ***P < 0.001.